"RIV/00216208:11120/09:00001931" . "D\u017Eupov\u00E1, Olga" . "tigecycline; tetracyclin; antibiotic treatment; multi-resistant pathogens"@en . . . "Bene\u0161, Ji\u0159\u00ED" . "RIV/00216208:11120/09:00001931!RIV10-MSM-11120___" . "Tigecyklin: Za\u0159azen\u00ED mezi ostatn\u00EDmi antibiotiky, vlastnosti, klinick\u00E9 vyu\u017Eit\u00ED"@cs . "Tigecycline: Its position between other antibiotics, features, clinical usage"@en . . "346333" . "Tigecycline belong to glycylcycline antibiotics. This new group of antibiotics was derived from lipophilic tetracyclines but differs from them by higher effectivity, lower affinity to bacterial resistance mechanisms, and very long half-time. Tigecycline is registered for treatment two groups of infections: skin and soft tissue infections and complicated intra-abdominal infections. Nevertheless, its therapeutic use probably can be enlarged to pneumonia, STD, infections caused by multi-resistant Helicobacter pylori, subacute and chronic infections associated with biofilm formation, and serious infections caused by intracelular pathogens (serious brucellosis, Q-fever, rickettsial infections). By contrast, tigecycline seems not appropriate for treatment sepsis and similar acute life-threatening bacterial diseases."@en . . "1" . . "Tigecyklin je antibiotikum pat\u0159\u00EDc\u00ED mezi glycylcykliny. Tato nov\u011B konstituovan\u00E1 skupina je odvozena od lipofiln\u00EDch tetracyklin\u016F, odli\u0161uje se v\u0161ak od nich vy\u0161\u0161\u00ED \u00FA\u010Dinnost\u00ED, odolnost\u00ED v\u016F\u010Di nej\u010Dast\u011Bj\u0161\u00EDm mechanizm\u016Fm rezistence, a tak\u00E9 mimo\u0159\u00E1dn\u011B dlouh\u00FDm biologick\u00FDm polo\u010Dasem. Tigecyklin je registrov\u00E1n k l\u00E9\u010Db\u011B infekc\u00ED k\u016F\u017Ee a m\u011Bkk\u00FDch tk\u00E1n\u00ED a k l\u00E9\u010Db\u011B komplikovan\u00FDch intraabdomin\u00E1ln\u00EDch infekc\u00ED, jeho klinick\u00E9 pou\u017Eit\u00ED v\u0161ak m\u016F\u017Ee b\u00FDt podstatn\u011B \u0161ir\u0161\u00ED. Dal\u0161\u00EDmi perspektivn\u00EDmi indikacemi jsou pneumonie, pohlavn\u011B p\u0159enosn\u00E9 nemoci, infekce zp\u016Fsoben\u00E9 multirezistentn\u00EDmi kmeny Helicobacter pylori, subakutn\u00ED a chronick\u00E9 infekce prov\u00E1zen\u00E9 tvorbou biofilmu a infekce vyvolan\u00E9 intracelul\u00E1rn\u00EDmi patogeny (brucel\u00F3zy, Q-hore\u010Dka, rickettsiov\u00E9 infekce). Naopak, tigecyklin se nejev\u00ED jako vhodn\u00E9 antibiotikum pro l\u00E9\u010Dbu seps\u00ED a podobn\u00FDch akutn\u011B prob\u00EDhaj\u00EDc\u00EDch t\u011B\u017Ek\u00FDch bakteri\u00E1ln\u00EDch infekc\u00ED." . . "Tigecycline: Its position between other antibiotics, features, clinical usage"@en . "Klinick\u00E1 mikrobiologie a infek\u010Dn\u00ED l\u00E9ka\u0159stv\u00ED" . . "Tigecyklin: Za\u0159azen\u00ED mezi ostatn\u00EDmi antibiotiky, vlastnosti, klinick\u00E9 vyu\u017Eit\u00ED" . . . "S" . . . "2"^^ . "[BE7B2293F604]" . "Tigecyklin: Za\u0159azen\u00ED mezi ostatn\u00EDmi antibiotiky, vlastnosti, klinick\u00E9 vyu\u017Eit\u00ED"@cs . "7"^^ . . . "2"^^ . . "1211-264X" . "15" . "CZ - \u010Cesk\u00E1 republika" . . "11120" . . "Tigecyklin je antibiotikum pat\u0159\u00EDc\u00ED mezi glycylcykliny. Tato nov\u011B konstituovan\u00E1 skupina je odvozena od lipofiln\u00EDch tetracyklin\u016F, odli\u0161uje se v\u0161ak od nich vy\u0161\u0161\u00ED \u00FA\u010Dinnost\u00ED, odolnost\u00ED v\u016F\u010Di nej\u010Dast\u011Bj\u0161\u00EDm mechanizm\u016Fm rezistence, a tak\u00E9 mimo\u0159\u00E1dn\u011B dlouh\u00FDm biologick\u00FDm polo\u010Dasem. Tigecyklin je registrov\u00E1n k l\u00E9\u010Db\u011B infekc\u00ED k\u016F\u017Ee a m\u011Bkk\u00FDch tk\u00E1n\u00ED a k l\u00E9\u010Db\u011B komplikovan\u00FDch intraabdomin\u00E1ln\u00EDch infekc\u00ED, jeho klinick\u00E9 pou\u017Eit\u00ED v\u0161ak m\u016F\u017Ee b\u00FDt podstatn\u011B \u0161ir\u0161\u00ED. Dal\u0161\u00EDmi perspektivn\u00EDmi indikacemi jsou pneumonie, pohlavn\u011B p\u0159enosn\u00E9 nemoci, infekce zp\u016Fsoben\u00E9 multirezistentn\u00EDmi kmeny Helicobacter pylori, subakutn\u00ED a chronick\u00E9 infekce prov\u00E1zen\u00E9 tvorbou biofilmu a infekce vyvolan\u00E9 intracelul\u00E1rn\u00EDmi patogeny (brucel\u00F3zy, Q-hore\u010Dka, rickettsiov\u00E9 infekce). Naopak, tigecyklin se nejev\u00ED jako vhodn\u00E9 antibiotikum pro l\u00E9\u010Dbu seps\u00ED a podobn\u00FDch akutn\u011B prob\u00EDhaj\u00EDc\u00EDch t\u011B\u017Ek\u00FDch bakteri\u00E1ln\u00EDch infekc\u00ED."@cs . "Tigecyklin: Za\u0159azen\u00ED mezi ostatn\u00EDmi antibiotiky, vlastnosti, klinick\u00E9 vyu\u017Eit\u00ED" .